(Q37994234)

26 August 2017

title

The role of natural killer cells in immunity against multiple myeloma (English)

1 reference

26 August 2017

James Godfrey

1

1 reference

26 August 2017

Don M Benson

series ordinal

2

1 reference

26 August 2017

language of work or name

1 reference

19 April 2012

1 reference

26 August 2017

1 reference

26 August 2017

volume

53

1 reference

26 August 2017

issue

9

1 reference

26 August 2017

page(s)

1666-1676

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.676175

26 August 2017

1 reference

From myeloma precursor disease to multiple myeloma: new diagnostic concepts and opportunities for early intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.676175

Improved survival in multiple myeloma and the impact of novel therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.676175

Immunodeficiency and immunotherapy in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.676175

Human natural killer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.676175

Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic acid allogeneic tumors. I. Distribution of reactivity and specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.676175

„Natural”︁ killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.676175

Innate or adaptive immunity? The example of natural killer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.676175

Activation, coactivation, and costimulation of resting human natural killer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.676175

Natural killer cell receptors: new biology and insights into the graft-versus-leukemia effect

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.676175

Functionally and structurally distinct NK cell receptor repertoires in the peripheral blood of two human donors

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.676175

MHC class I molecules and KIRs in human history, health and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.676175

Human NK cell education by inhibitory receptors for MHC class I.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.676175

Natural killer cell signaling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.676175

Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.676175

Identification of PVR (CD155) and Nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.676175

Crystal structure of human natural cytotoxicity receptor NKp30 and identification of its ligand binding site

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.676175

Recognition of haemagglutinins on virus-infected cells by NKp46 activates lysis by human NK cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.676175

Activation of NK cell cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.676175

Anti-myeloma activity of natural killer lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.676175

Analysis of natural killer-associated antigens in peripheral blood and bone marrow of multiple myeloma patients and prognostic implications.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.676175

Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.676175

Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.676175

CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.676175

In vivo peripheral expansion of naive CD4+CD25high FoxP3+ regulatory T cells in patients with multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.676175

TGF-beta utilizes SMAD3 to inhibit CD16-mediated IFN-gamma production and antibody-dependent cellular cytotoxicity in human NK cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.676175

Pro- and antiinflammatory cytokine signaling: reciprocal antagonism regulates interferon-gamma production by human natural killer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.676175

Impairment of natural killer functions by interleukin 6 increases lymphoblastoid cell tumorigenicity in athymic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.676175

Interleukin 12 and tumor necrosis factor alpha are costimulators of interferon gamma production by natural killer cells in severe combined immunodeficiency mice with listeriosis, and interleukin 10 is a physiologic antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.676175

Interleukin 10 (IL-10) inhibits human lymphocyte interferon gamma-production by suppressing natural killer cell stimulatory factor/IL-12 synthesis in accessory cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.676175

Cyclooxygenase-2 (COX-2) is frequently expressed in multiple myeloma and is an independent predictor of poor outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.676175

Overexpression of cyclooxygenase-2 in multiple myeloma: association with reduced survival

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.676175

Oncogenic RAS mutations in myeloma cells selectively induce cox-2 expression, which participates in enhanced adhesion to fibronectin and chemoresistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.676175

Prostaglandin E(2) (PGE (2)) suppresses natural killer cell function primarily through the PGE(2) receptor EP4

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.676175

Cell-surface association between matrix metalloproteinases and integrins: role of the complexes in leukocyte migration and cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.676175

Elevated IL-17 produced by TH17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.676175

CD4+CD25+FoxP3+regulatory T cells are increased whilst CD3+CD4−CD8−αβTCR+Double Negative T cells are decreased in the peripheral blood of patients with multiple myeloma which correlates with disease burden

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.676175

Impact of intracellular alpha fetoprotein on retinoic acid receptors-mediated expression of GADD153 in human hepatoma cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.676175

Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.676175

Novel role for STAT3 in transcriptional regulation of NK immune cell targeting receptor MICA on cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.676175

Stem cell factor and interleukin-2/15 combine to enhance MAPK-mediated proliferation of human natural killer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.676175

Interleukin-2, interleukin-15, and their roles in human natural killer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.676175

A potential role for interleukin-15 in the regulation of human natural killer cell survival

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.676175

Interleukin (IL)-15Rα–deficient Natural Killer Cells Survive in Normal but Not IL-15Rα–deficient Mice

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.676175

The requirement for DNAM-1, NKG2D, and NKp46 in the natural killer cell-mediated killing of myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.676175

MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.676175

HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.676175

Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.676175

The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.676175

ATM-ATR-dependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK-cell susceptibility and is associated with a senescent phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.676175

Interferons in the treatment of human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.676175

Lymphocyte recovery and clinical response in multiple myeloma patients receiving interferon alpha 2 beta after intensive therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.676175

Cell-mediated toxicity of interleukin-2-activated lymphocytes against autologous and allogeneic human myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.676175

Malignant plasma cells are sensitive to LAK cell lysis: pre-clinical and clinical studies of interleukin 2 in the treatment of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.676175

Immunomodulation of early engrafted natural killer cells with interleukin-2 and interferon-alpha in autologous stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.676175

The dose of infused lymphocytes in the autograft directly correlates with clinical outcome after autologous peripheral blood hematopoietic stem cell transplantation in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.676175

Prognostic significance of platelet recovery pattern after allogeneic HLA-identical sibling transplantation and its association with severe acute GVHD.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.676175

Higher infused lymphocyte dose predicts higher lymphocyte recovery, which in turn, predicts superior overall survival following autologous hematopoietic stem cell transplantation for multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.676175

Re-infused autologous graft natural killer cells correlates with absolute lymphocyte count recovery after autologous stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.676175

International Myeloma Working Group consensus statement regarding the current status of allogeneic stem-cell transplantation for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.676175

Progress in allogeneic transplantation for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.676175

Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.676175

Comparison between antithymocyte globulin and alemtuzumab and the possible impact of KIR-ligand mismatch after dose-reduced conditioning and unrelated stem cell transplantation in patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.676175

Infusion of haplo-identical killer immunoglobulin-like receptor ligand mismatched NK cells for relapsed myeloma in the setting of autologous stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.676175

Lenalidomide as salvage therapy after allo-SCT for multiple myeloma is effective and leads to an increase of activated NK (NKp44(+)) and T (HLA-DR(+)) cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.676175

Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.676175

Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.676175

Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.676175

Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.676175

Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.676175

Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.676175

IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.676175

Dexamethasone synergizes with lenalidomide to inhibit multiple myeloma tumor growth, but reduces lenalidomide-induced immunomodulation of T and NK cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.676175

Bortezomib down-regulates the cell-surface expression of HLA class I and enhances natural killer cell-mediated lysis of myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.676175

Proteasome inhibitor lactacystin augments natural killer cell cytotoxicity of myeloma via downregulation of HLA class I.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.676175

Sensitization of tumor cells to NK cell-mediated killing by proteasome inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.676175

CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.676175

Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.676175

Influence of CRACC, a SLAM family receptor coupled to the adaptor EAT-2, on natural killer cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.676175

Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.676175

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.676175

A phase 2 study of bortezomib in relapsed, refractory myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.676175

Role of KIRs and KIR ligands in hematopoietic transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.676175

Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.676175

Monoclonal antibodies in the treatment of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.676175

Surface molecule CD229 as a novel target for the diagnosis and treatment of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.676175

Immunomodulatory drugs Revlimid (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.676175

Histone deacetylase inhibitors sensitize tumour cells for cytotoxic effects of natural killer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.676175

Heat shock protein-90 inhibitors increase MHC class I-related chain A and B ligand expression on multiple myeloma cells and their ability to trigger NK cell degranulation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.676175

Safety analysis of ex vivo-expanded NK and NK-like T cells administered to cancer patients: a phase I clinical study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.676175

Natural killer cell frequency and serum cytokine levels in monoclonal gammopathies: correlation of bone marrow granular lymphocytes to prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.676175

The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.676175

10.3109/10428194.2012.676175

21 January 2018

Identifiers

DOI

1 reference

26 August 2017

1 reference